Edition:
United Kingdom

Eyenovia Inc (EYEN.OQ)

EYEN.OQ on NASDAQ Stock Exchange Capital Market

6.50USD
20 Jul 2018
Change (% chg)

$-0.09 (-1.37%)
Prev Close
$6.59
Open
$6.80
Day's High
$6.81
Day's Low
$6.38
Volume
3,310
Avg. Vol
2,456
52-wk High
$10.60
52-wk Low
$5.86

Chart for

About

Eyenovia, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of ophthalmology products utilizing its piezo-print technology to deliver micro-doses of active pharmaceutical ingredients (micro-therapeutics) to the eye. Its product candidates include MicroProst, MicroStat, MicroTears... (more)

Overall

No Ratios Available.

Financials

  EYEN.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -- -- --
ROI: -- 15.07 14.61
ROE: -- 16.60 16.34

BRIEF-Eyenovia Reports Q1 Loss Per Share Of $0.45

* EYENOVIA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND COMPLETION OF EYN PG21 STUDY

09 May 2018

BRIEF-Eyenovia Reports Q4 Loss Per Share $0.84

* EYENOVIA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

02 Apr 2018

BRIEF-Eyenovia Appoints Three Industry Veterans To Board Of Directors

* EYENOVIA APPOINTS THREE INDUSTRY VETERANS TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

26 Mar 2018

BRIEF-Eyenovia Advances Micropine For Myopia Into Phase III Clinical Development

* EYENOVIA ADVANCES MICROPINE FOR MYOPIA INTO PHASE III CLINICAL DEVELOPMENT AND APPOINTS STANFORD PROFESSOR DR. DOUGLAS FREDRICK TO ITS SCIENTIFIC ADVISORY BOARD AND MYOPIA PROGRAM STEERING COMMITTEE

21 Feb 2018

BRIEF-Fred Eshelman Reports 15 Pct Stake In Eyenovia Inc

* FRED ESHELMAN REPORTS 15.0 PERCENT STAKE IN EYENOVIA INC AS OF JANUARY 29, 2018 - SEC FILING‍​ Source text : (http://bit.ly/2EWoPJS) Further company coverage:

21 Feb 2018

BRIEF-Shuhei Yoshida Reports 15.1% Passive Stake In Eyenovia As Of Jan 29, 2018

* SHUHEI YOSHIDA REPORTS 15.1 PERCENT PASSIVE STAKE IN EYENOVIA INC AS OF JANUARY 29, 2018 - SEC FILING Source text: http://bit.ly/2C7zbpb Further company coverage:

20 Feb 2018

Earnings vs. Estimates